Twist Bioscience Stock Falls 14% as Investors Question Profitability and Over‑Hyped Growth
Twist Bioscience stock drops 13.95% as investors question its profitability, revealing the risks of overhyped biotech innovation.
- TWIST BIOSCIENCE CORP
- United States
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read